Engflag

Crima

Quick links to important sections

Crima

There is no image.

Method of action: Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Meningitis, Bacteremia, Bronchitis, Bronchiectasis, Bursitis, Gonorrhea, Infection, Infection,Bacterial, Infection,Urinary Tract

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crima

Property Description
Active ingredient Ceftazidime (INN)
Form Sterile Powder for Injection
Pharmacological class Third-Generation Cephalosporin Antibiotic
General Purpose Broad-spectrum antibacterial action
Origin Synthetic

Defining the Medicine and its Class

Crima is a brand name for a potent, synthetic antibacterial agent whose active substance is Ceftazidime, definitively classified as a third-generation cephalosporin and a beta-lactam antibiotic. This medicine belongs to a major class of antibiotics designed to combat serious bacterial infections throughout the body. The medication's status as a prescription-only medicine (POM) is globally consistent, underscoring its use in managed healthcare settings. As a beta-lactam, its chemical structure enables it to perform a definitive, cell-killing action, known as bactericidal action, against susceptible microorganisms. The classification as a third-generation agent is clinically recognized for offering a favorable balance of broad activity and stability compared to earlier cephalosporins.

Form, Composition, and General Purpose

The active ingredient Ceftazidime is primarily supplied under the Crima brand as a sterile powder for injection within a sealed vial, making it a single-entity product. The powder must be reconstituted with a sterile vehicle, such as sterile water for injection, immediately before use, as it is intended for rapid parenteral administration (by injection) into the bloodstream or muscle. The medicine's general purpose is to act as a broad-spectrum antibacterial agent to eliminate susceptible pathogens causing systemic infections. A typical scenario for its use involves treating severe infections in adults and pediatric patients when the specific pathogen is unknown but is suspected to be susceptible to this drug class.

Why is a Third-Generation Cephalosporin Used?

This class of medication is used because of its targeted and reliable ability to kill critical bacteria, including many challenging Gram-negative pathogens such as Pseudomonas aeruginosa. The enhanced molecular features of Ceftazidime confer significant resistance to the beta-lactamase enzymes that many resistant bacteria produce to disable common antibiotics. This stability ensures the therapeutic molecule remains active, penetrating bacterial defenses to disrupt their cell wall synthesis, making Crima a critical tool for managing serious, potentially difficult-to-treat bacterial pathology.

Regulatory References

  1. bactericidal action
  2. third-generation cephalosporin

What side effects are possible with Crima?

Possible Side Effects and Safety Information

The information in this section outlines the adverse reactions and safety characteristics of Crima (Ceftazidime) as documented in official government regulatory sources, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This summary is strictly based on labeled safety data and is not intended as medical advice or instruction for use.

Frequency-Classified Adverse Reactions

The documented side effects are classified by their expected frequency:

Frequency Category Examples of Documented Reactions
Common (1/100 to <1/10) Diarrhea, Eosinophilia, Thrombocytosis, Maculopapular rash, Urticaria, Pruritus, and inflammation or pain at the injection site.
Uncommon (1/1,000 to <1/100) Headache, Dizziness, Nausea, Vomiting, Abdominal pain, Candidiasis, Colitis, and transient increases in blood urea or serum creatinine.
Not Known (Frequency cannot be estimated) Anaphylaxis, Seizures, Encephalopathy, Toxic Epidermal Necrolysis (TEN), Stevens-Johnson syndrome (SJS), and Toxic Nephropathy.

Serious Adverse Reactions and Safety Constraints

Official labeling identifies several adverse reactions as serious or clinically significant:

  • Hypersensitivity and Anaphylaxis: Severe, systemic allergic reactions, including anaphylaxis, are documented.
  • Neurotoxicity: Serious nervous system effects, such as Encephalopathy, Seizures, and Coma, have been reported.
  • Severe Skin and Gastrointestinal Reactions: This includes life-threatening skin conditions (SJS, TEN) and Pseudomembranous Colitis.

Safety Restrictions: Crima is contraindicated in individuals with a known hypersensitivity to Ceftazidime, any cephalosporin, or a history of severe immediate hypersensitivity to other beta-lactam antibiotics (e.g., penicillins).

Population-Specific Note: Patients with pre-existing renal impairment are at a higher risk of developing neurotoxic effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Crima (Ceftazidime) as primarily involving severe neurological adverse reactions due to excessively high concentrations of the active substance in the body. These high concentrations are particularly associated with patients who have impaired renal function.

Documented Overdose Manifestations

Classification Manifestation/Required Action
Symptom Cluster Seizure activity (convulsions), encephalopathy (brain disorder), myoclonus (jerking), asterixis, paraesthesia.
Severe Outcomes Overdosage may result in severe, life-threatening, or fatal occurrences of neurological events.
Key Risk Factor Increased severity and risk of neurological reactions in patients with renal impairment (kidney disease).

Regulator-Mandated Emergency Actions

The onset of severe neurological symptoms requires immediate emergency medical attention. Regulator guidance requires that individuals seek emergency medical help immediately or contact a doctor or nurse immediately if they experience severe nervous system disorders such as fits or coma.

Overdose management is documented as being symptomatic and supportive. In cases of overdosage, procedural measures such as haemodialysis may be used to assist in removing the substance from the systemic circulation, as no specific antidote is officially available. Patients who have received an acute overdosage must be carefully observed.

Therapeutic Uses of Crima

Understanding Crima: Main Uses and Benefits

Crima (glimepiride) is an oral antihyperglycemic medication belonging to the sulfonylurea class. It is primarily utilized in the management of type 2 diabetes mellitus, a chronic condition where the body does not use insulin properly or cannot produce enough of it to maintain healthy blood glucose levels.

Primary Indications

The medication is indicated for the improvement of glycemic control in adults with type 2 diabetes. Its function is centered on helping the body regulate the amount of sugar in the blood. It is important to note that this medication is specifically for type 2 diabetes and is not used for the treatment of type 1 diabetes or diabetic ketoacidosis.

Mechanism of Action

Crima works by stimulating the beta cells in the pancreas to release more insulin. Insulin is the hormone responsible for allowing sugar to enter the body's cells to be used for energy. By increasing insulin secretion, the medication helps lower elevated blood glucose levels that occur after eating and during periods of fasting.

Therapeutic Benefits

When integrated into a comprehensive management plan, Crima provides several clinical benefits focused on long-term health stability:

  • Blood Sugar Regulation: The primary benefit is the consistent reduction of hemoglobin A1c (HbA1c) levels, which reflects average blood sugar control over a period of two to three months.
  • Prevention of Hyperglycemia: By assisting the pancreas in responding to glucose, it helps prevent the spikes in blood sugar that can lead to immediate symptoms like fatigue, blurred vision, and increased thirst.
  • Long-term Health Support: Maintaining blood glucose within a target range is essential for reducing the risk of chronic complications associated with diabetes, such as damage to the kidneys, nerves, and eyes.

Role in Diabetes Management

Crima is most effective when used as part of a therapeutic regimen that includes specific dietary modifications and regular physical activity. While the medication assists in chemical glucose regulation, lifestyle factors remain the foundation of managing insulin sensitivity and overall metabolic health. It may be used as a standalone therapy (monotherapy) or in combination with other glucose-lowering agents when a single medication is insufficient to meet glycemic goals.

Eligibility and Restrictions for Use

Who Can and Cannot Use Crima?

This section outlines the official population eligibility and non-eligibility rules for Crima (Ceftazidime), as defined by government regulatory documents.

Absolute Contraindications

Crima is contraindicated and must not be used by patients with a history of serious hypersensitivity or allergic reaction to Ceftazidime itself, to any antibiotic in the cephalosporin class, or to any other beta-lactam antibiotic (such as penicillins).

Age-Group Eligibility

Crima is indicated for use in adults and pediatric patients, including neonates (from birth). Special consideration is required for older adults over 80 years of age due to potential age-related reduction in drug clearance. For certain fixed-dose formulations, use is not recommended for children requiring fractional doses.

Conditional Use and Restrictions

Use is restricted for patients with impaired renal function (Creatinine Clearance le 50 mL/min). This necessitates specialized management because reduced kidney function increases the risk of neurological adverse reactions. For pregnant patients, use is conditional and authorized only if the potential benefit outweighs the potential risk. Use during lactation is generally considered acceptable, as the drug is excreted in low levels in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Crima (Ceftazidime), categorized by their potential effect on toxicology, efficacy, or pharmacokinetics. The co-administration of Aminoglycoside Antibiotics (e.g., Gentamicin) may increase the risk of nephrotoxicity and ototoxicity, representing an additive toxicity risk. The combination with Chloramphenicol has been observed to cause antagonistic effects that reduce bactericidal activity and is officially noted to be avoided when maximal therapeutic effect is desired.

Documented Interaction Effects

Interacting Product Category Official Interaction Statement
Oral Anticoagulants (e.g., Warfarin) May increase the anticoagulant activities of these medicines.
Hormonal Contraceptives May reduce the effectiveness of the hormonal agent.
Probenecid Administration has no effect on Ceftazidime's elimination kinetics.

Ceftazidime is eliminated primarily by the kidneys. Consequently, high and prolonged serum concentrations occur in patients with impaired renal function, which increases the official risk of neurologic adverse reactions, including seizures. Furthermore, Ceftazidime may cause a false-positive reaction for glucose in the urine when tested using copper reduction methods (such as CLINITEST® tablets), requiring the use of enzymatic glucose oxidase tests.

Mechanism of Action

The Mechanism of Lethal Cell Wall Disruption

The core action of Ceftazidime involves the irreversible inhibition of essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). The molecule forms a stable, covalent bond with the PBPs, preventing them from catalyzing the final step of peptidoglycan cross-linking, which is necessary to build the rigid bacterial cell wall. This specific molecular blockade leads to a critical structural failure where the bacterium can no longer withstand its internal osmotic pressure, triggering rapid cell lysis (rupture) and destruction. The resulting mechanism is categorized as bactericidal.

Overcoming Bacterial Resistance and Mechanistic Limits

Ceftazidime’s molecular structure confers intrinsic stability against destruction by many common beta-lactamase enzymes, which helps the drug reach its PBP target. However, the mechanism faces limitations from highly specialized bacterial defenses, such as Extended-Spectrum beta-Lactamases (ESBLs), which can inactivate the drug. Additionally, bacterial efflux pumps can actively remove the molecule from the cell, preventing it from achieving the inhibitory concentration required for PBP acylation.

Dosage and Administration Information

Crima (Ceftazidime) is administered only via the parenteral route, meaning it is delivered as an intravenous (IV) infusion or injection, or as an intramuscular (IM) injection. The medicine is supplied as a sterile powder that requires mandatory reconstitution with a specified sterile diluent, such as sterile water for injection, immediately before use. For IV administration, the dose is typically infused over a 30-minute period.

The standard adult regimen is a dose of 1 g to 2 g, typically administered every 8 to 12 hours. For serious or life-threatening infections, an increased dose frequency of 2 g every 8 hours may be used, though the maximum total daily dose should generally not exceed 6 g. The duration of treatment is commonly 7 to 14 days, and it is generally recommended to continue the regimen for at least two days after the signs of infection have resolved.

Special administration rules apply to specific populations. Patients with impaired renal function must have their dosage reduced and/or their administration interval adjusted based on the patient’s measured Creatinine Clearance (CLCr). For children aged one month to 12 years, dosing is determined by body weight, often ranging from 90 to 150 mg/kg per day, divided into three equal doses. Procedurally, the reconstituted solution should not be mixed in the same container with certain other medications, such as aminoglycoside antibiotics.

Recent Clinical Evidence

Research evidence / Overview of Studies for Crima (Ceftazidime)

This section provides an overview of the research studies and clinical trials that have been conducted for Crima (Ceftazidime), describing the focus of the research and the populations that have been observed, without providing personal medical advice or making claims about guaranteed results. The studies help show what has been observed so far in group patterns.

Evidence for Use in Bacterial Septicemia

Research exploring Crima in the context of severe systemic infections, such as Bacterial Septicemia, was studied in various Randomized Controlled Trials (RCTs) and Systematic Reviews. These research efforts primarily examined the short-term outcomes related to systemic or functional imbalance observed during the infection. Researchers monitored clinical response status, microbiological clearance (the measured absence of the organism), and short-term outcomes such as all-cause mortality and length of hospital stay.

Evidence for Use in Severe Respiratory Infections

Crima was evaluated in studies focusing on severe conditions associated with acute or disruptive episodes, specifically complicated Lower Respiratory Tract Infections, often in hospital and intensive care settings. Studies explored outcomes related to physical discomfort and systemic strain observed in these conditions. The research examined measurements of clinical response (e.g., changes in respiratory status) and measurements related to microbiological status in respiratory samples.

Evidence for Empirical Therapy in Febrile Neutropenia

Crima was evaluated in research that explored an initial, or empirical, strategy for Febrile Neutropenia—a high-risk condition presenting with temporary physiological imbalance in immunocompromised cancer patients. The main outcomes studied were the time tracked for fever to subside (defervescence) without needing a change to a different regimen, and overall survival rates during the acute neutropenic episode.

Study Focus and Evidence Gaps

Long-Term Follow-up and Durability of Response

Given that Crima is an antibiotic designed to address acute infections, the typical follow-up durations were limited, generally to the end of treatment and a short period thereafter (e.g., 28 to 30 days). There is limited information for long-term outcomes regarding the durability of the microbiological response or the recurrence of infection in the months and years following treatment.

What Remains Uncertain in the Research Record

The evidence base, while extensive for acute care, contains certain limitations. Subgroup findings are uncertain in some specialized areas (e.g., pregnant populations). Comparative evidence is lacking in some contexts against the newest generation of combination antibiotics, as the research is ongoing and continually updating. The results apply only to the populations studied under specific trial conditions, and research does not determine whether an individual will respond similarly outside of those controlled settings.

Frequently Asked Questions (FAQ)

Common questions about Crima (FAQ)

Q: Can Crima be used for conditions other than its main approved use?

Crima (Ceftazidime) is officially approved for treating specific infections, such as those in the lower respiratory tract, urinary tract, and for severe systemic infections. The medicine may be considered by healthcare professionals for other serious conditions not listed on the official label if they determine the potential benefits outweigh the risks. This practice, where a medication is used outside of its official indications, is a decision made by the healthcare provider.

Q: Does Crima affect driving or operating machinery?

Official regulatory documents list side effects like dizziness and headache for Crima, which may potentially affect mental alertness. Official labeling advises that patients should be aware of how they respond to the medicine before deciding to drive or operate machinery.

Q: Why is Crima sometimes prescribed 'off-label'?

Crima is a powerful, broad-spectrum antibiotic known for its strong action against certain difficult-to-treat bacteria. Its stability and activity against certain pathogens lead healthcare professionals to consider it for a range of serious infections, even those outside the official indications, when they determine it is clinically appropriate.

Q: Is Crima a controlled substance?

No. According to government regulatory documents, Crima (Ceftazidime) is not classified as a controlled substance. It is legally classified as a prescription-only medicine.

Q: Does Crima show up on a standard drug test?

Crima itself is not a substance typically screened for in standard drug tests. However, official information indicates that Crima may cause a false-positive reaction for glucose in the urine when tests use older, copper-reduction methods (like CLINITEST® tablets). If a glucose test is required, an enzymatic glucose oxidase method must be used instead.

Q: Does Crima affect blood pressure?

The official safety documentation lists low blood pressure (hypotension) as a possible effect, generally in the context of a severe adverse reaction or overexposure to the medicine. It is not typically listed as a common, expected side effect.

Q: Is there a generic version of Crima available?

Yes. The active ingredient in Crima, which is Ceftazidime, is available as a generic drug for injection. This status is reflected in the official drug product regulatory records.

Q: What's the difference between the tablet and capsule forms of Crima?

Crima (Ceftazidime) is typically not supplied as a tablet or capsule. The official dosage form is a sterile powder for injection. This powder is mixed with a sterile liquid before being administered intravenously (IV) or intramuscularly (IM).

Q: Is it safe to stop taking Crima suddenly?

Official labeling advises that the full course of therapy should be completed as prescribed, even if symptoms show early improvement. Stopping or skipping doses may increase the potential for bacteria to develop resistance to the antibiotic.

Q: Can Crima affect fertility?

Regulatory documents indicate that animal studies have revealed no evidence of impaired fertility. Specific and adequate studies in pregnant women are limited, and use is evaluated by the healthcare professional.

Q: Does Crima help with chronic pain?

Crima is classified as an antibiotic, and its only approved use is for treating susceptible bacterial infections. Its official labeling does not include the treatment or management of any form of chronic pain.

Q: Why is Crima being studied so much lately?

The medicine and its related combination products are the focus of ongoing clinical research. Studies are often aimed at optimizing treatment strategies for severe, complicated infections, particularly those caused by bacteria that have developed resistance to existing therapies.

Q: How does Crima differ from other similar drugs on the market?

Crima is specifically classified as a third-generation cephalosporin antibiotic. Its unique molecular structure provides stability against many bacterial defense enzymes, allowing it to effectively target and kill critical Gram-negative pathogens, such as Pseudomonas aeruginosa.

Q: Is Crima safe for long-term use?

Crima is an antibiotic prescribed for acute bacterial infections, with a typical treatment duration of 7 to 14 days. Since it is intended for short-term, acute use, regulatory documents do not provide information on its safety for prolonged use. Prolonged use, as noted in the official prescribing information, may lead to the potential for overgrowth of non-susceptible organisms, which would require re-evaluation.

Q: Are there any vitamins or supplements that interact with Crima?

The official drug label does not list specific interactions with general vitamins or supplements. However, official prescribing information notes that cephalosporins may affect blood clotting activity in certain patients, and in these cases, the administration of Vitamin K may be considered by a healthcare professional.

Q: Is it normal to feel a little dizzy after starting Crima?

Dizziness is listed in the official safety documents as an uncommon side effect. If this side effect or any other becomes bothersome or persistent, it is important to bring it to the attention of a healthcare professional.

Q: Does Crima interact with blood thinners?

Yes. The official information states that taking Crima with oral anticoagulants (often referred to as blood thinners) may increase the activity of the anticoagulant. For patients receiving this combination, official labeling advises that their blood clotting time should be monitored by a healthcare professional.

Q: What is the success rate typically associated with Crima treatment?

Official regulatory data refers to clinical study outcomes by measuring clinical response status (how symptoms change) and microbiological clearance (whether the bacteria are eliminated). The documents do not provide a single, universal 'success rate' percentage, as outcomes vary based on the type and severity of the specific infection being treated.

Q: Can I take Crima if I have a history of kidney or liver problems?

Official labeling warns that patients with impaired renal (kidney) function need specialized management, which typically involves adjusting the dose and monitoring to reduce the risk of neurological side effects. However, for patients with only liver problems, a dosage adjustment is generally not required if the kidney function is normal.

Q: Does taking Crima require regular blood tests?

Official prescribing information states that kidney function monitoring is necessary for at-risk patients, and blood clotting time monitoring is advised if the patient is taking blood thinners. The label does not mandate regular blood tests for the general population.

Q: What if Crima doesn't seem to be working after a few weeks?

Official guidance advises that a patient should bring it to the attention of their healthcare professional if their symptoms do not start to improve within a few days, or if they become worse. Ongoing evaluation is necessary to determine if the course of treatment should be adjusted.

How should Crima be stored and disposed of?

How to Store and Dispose of Crima?

The sterile powder of Crima (ceftazidime) requires specific storage conditions to maintain its quality. The unreconstituted powder must be stored at 20 C to 25 C (68 F to 77 F) and kept in its original outer carton for protection from light.

Stability and Disposal

Once reconstituted, the solution should ideally be used immediately. However, the solution maintains chemical and physical stability for up to 24 hours when refrigerated (2 C to 8 C). The product is for single use only, and any unused solution must be discarded according to local guidelines for medicinal waste. It is mandatory to keep this medicine out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Crima found in:

A-Z Index: